PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs (Q39584693)

13 September 2017

PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs (English)

1 reference

13 September 2017

1 reference

3

1 reference

13 September 2017

B Weigelt

1

1 reference

PubMed ID

21358673

13 September 2017

P H Warne

series ordinal

2

1 reference

PubMed ID

21358673

13 September 2017

language of work or name

English

0 references

publication date

28 February 2011

1 reference

13 September 2017

1 reference

13 September 2017

30

1 reference

13 September 2017

3222-3233

1 reference

13 September 2017

29

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2011.42

13 September 2017

0 references

cites work

Integrated profiling of basal and luminal breast cancers.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Cell line misidentification: the beginning of the end

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

The PIK3CA gene is mutated with high frequency in human breast cancers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

A mammalian protein targeted by G1-arresting rapamycin-receptor complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

mTOR signaling and drug development in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Genome remodelling in a basal-like breast cancer metastasis and xenograft

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

mTOR and cancer: many loops in one pathway.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Identification of a novel inhibitor of mitogen-activated protein kinase kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Defining the role of mTOR in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Rare cancer-specific mutations in PIK3CA show gain of function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Exploiting the PI3K/AKT pathway for cancer drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Genetic alterations and oncogenic pathways associated with breast cancer subtypes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

PIK3CA mutation associates with improved outcome in breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Three-dimensional culture models of normal and malignant breast epithelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Frequent mutation of the PIK3CA gene in ovarian and breast cancers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Targeting the phosphoinositide 3-kinase pathway in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

The third dimension bridges the gap between cell culture and live tissue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

A coding-independent function of gene and pseudogene mRNAs regulates tumour biology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

High frequency of mutations of the PIK3CA gene in human cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Fibroblast-derived 3D matrix differentially regulates the growth and drug-responsiveness of human cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Post-translational regulation of PTEN.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

PTEN-deficient cancers depend on PIK3CB.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Unraveling the microenvironmental influences on the normal mammary gland and breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Modeling tissue morphogenesis and cancer in 3D.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

PI3K pathway alterations in cancer: variations on a theme

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

PI(3)king apart PTEN's role in cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

31 March 2020

Identifiers

DOI

10.1038/ONC.2011.42

1 reference

13 September 2017

1 reference

PubMed ID

21358673